

Case Studies

Comparison studies of CellRx Short™ AE-IGF-1 to competitive products

Cell viability and IgG productivity


Objective

Compare the stimulatory effects of Short AE-IGF-1, LONG[®]R³ IGF-1, IGF-1 and Insulin on PER.C6 cell viability and IgG productivity.

Comparison of CellRx Short AE-IGF-1 and Sigma IGF-1 additives in PER.C6 for Cell Viability

- PER.C6 cell suspension was monitored for cell viability
- Medium is protein-free PerMab without growth factors
- Additives are indicated below
- All values in triplicate


Comparison of CellRx Short AE-IGF-1 and Sigma IGF-1 additives in PER.C6 for Cell Viability



Comparison of CellRx Short AE-IGF-1 and Sigma IGF-1 additives in PER.C6 for IgG productivity

- PER.C6 cell suspension was monitored for IgG productivity
- Medium is protein-free PerMab without growth factors
- Additives are indicated below
- All values in triplicate

Comparison of CellRx Short AE-IGF-1 and Sigma IGF-1 additives in PER.C6 for IgG productivity



Results

Stimulatory effect on cell growth and productivity was pronounced for all forms of IGF-1 and Insulin over the no supplement control.

DAY 10

Short AE-IGF-1 and LONG R³IGF-1 supplemented cultures produced approximately ~5% more IgG per unit volume over IGF-1 and 100% more than insulin fed cultures.

DAY 08

Short AE-IGF-1, LONGR³IGF-1 and IGF-1 supplemented cultures had 25% more viable cells than insulin fed cultures.

CellRx Short AE-IGF-1 is available for laboratory research and large-scale in-vitro biopharmaceutical manufacturing use only. Not for diagnostic or therapeutic use.

Short™AE-IGF-1 is a registered trademark of CellRx Ltd. (Synonyms include AE-IGF-1, RhShort AE-IGF-1, Short IGF). LONG® is a registered trademark of Novozymes Biopharma AU.



CellRx

CellRx Limited
12-14 Finch Road
Douglas, Isle of Man
cellrxbio.com